However, when established tumors were provided both Dox (to activate PTF1a) and gemcitabine, total tumor burden decreased by 55%, a 1.4‐fold enhancement in gemcitabine sensitivity (Fig. 8D,E). This evidence concerns the gene PTF1A and neoplasm.